Long-term Treatment of 189 Acromegalic Patients with the Somatostatin Analog Octreotide - Results of the International Multicenter Acromegaly Study Group
Vance, M. L.; Harris, Alan G; Beckers, Albert
1991 • In Archives of Internal Medicine, 151, p. 1573
Beckers, Albert ; Université de Liège - ULiège > Département des sciences cliniques > Endocrinologie
Language :
English
Title :
Long-term Treatment of 189 Acromegalic Patients with the Somatostatin Analog Octreotide - Results of the International Multicenter Acromegaly Study Group
Publication date :
August 1991
Journal title :
Archives of Internal Medicine
ISSN :
0003-9926
eISSN :
1538-3679
Publisher :
American Medical Association, United States - Illinois
Alexander L, Appleton D, Hall R, Ross WM, Wilkinson R. Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol. 1980;12:71-79.
Bengtsson BA, Eden S, Ernest I, Oden A, Sjogren B. Epidemiology and long-term survival in acromegaly. Acta Med Scand. 1988;223:237-235.
Wright AD, Hill DM, Lowy C, Fraser TR. Mortality in acromegaly. Q J Med. 1970;153:1-16.
Klein I, Parveen G, Gavaler JS, Vantheil DH. Colonic polyps in patients with acromegaly. Ann Intern Med. 1982;97:27-30.
Vance ML, Evans WS, Thorner MO. Drugs five years later: bromocriptine. Ann Intern Med. 1984;100:78-91.
Liuzzi A, Chiodini PG, Botalla L, Cremascoli G, Muller EE, Silvestrini F. Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-a-ergocriptine) administration. J Clin Endocrinol Metab. 1974;38:910-912.
Wass JAH, Thorner MO. Morris DV, et al. Long-term treatment of acromegaly with bromocriptine. BMJ. 1977;1:875-877.
Plewe G, Krause U, Beyer J, Neufeld M, del Pozo E. Long-acting and selective suppression of growth hormone secretion by somatostatin analogue SMS 201-995 in acromegaly. Lancet. 1984;2:782-784.
Lamberts SWJ, Uitterlinden P, Verschoor L, van Dongen KJ, del Pozo E. Long-term treatment of acromegaly with the somatostatin analogue SMS 201995. N Engl J Med. 1985;313:1576-1580.
Lamberts SWJ, Oosterom R, Neufeld M, del Pozo E. The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab. 1985;60:1161-1165.
Verschoor L, Lamberts SWJ, Uitterlinden P, del Pozo E. Glucose tolerance during long term treatment with a somatostatin analogue. BMJ. 1986;293:1327-1328.
Lamberts SWJ, Zweens M, Verschoor L, del Pozo E. A comparison among the growth hormone-lowering effects in acromegaly of the somatomedin analog SMS 201-995, bromocriptine, and the combination of both drugs. J Clin Endocrinol Metab. 1986;63:16-19.
Wass JA, Lytras N, Besser GM. Somatostatin octapeptide (SMS 201995) in the medical treatment of acromegaly. Scand J Gastroenterol Suppl. 1986;119:136-140.
Chiodini PG, Cozzi R, Dallabonzana D, et al. Medical treatment of acromegaly with SMS 201-995, a somatostatin analog: a comparison with bromocriptine. J Clin Endocrinol Metab. 1987;64:447-453.
Christensen SE, Weeke J, Orskov H, et al. Continuous subcutaneous pump infusion of somatostatin analogue SMS 201-995 versus subcutaneous injection schedule in acromegalic patients. Clin Endocrinol. 1987;27:297-306.
Ducasse MC, Tauber JP, Tourre A, et al. Shrinking of a growth hormone-producing pituitary tumor by continuous subcutaneous infusion of the somatostatin analog SMS 201-995. J Clin Endocrinol Metab. 1987;65:1042-1046.
George SR, Hegele RA, Burrow GN. The somatostatin analogue SMS 201-995 in acromegaly: prolonged, preferential suppression of growth hormone but not pancreatic hormones. Clin Invest Med. 1987;10:309-315.
Lamberts SWJ, Uitterlinden P, del Pozo E. SMS 201-995 induces a continuous decline in circulating growth hormone and somatomedin-C levels during therapy of acromegalic patients for over two years. J Clin Endocrinol Metab. 1987;65:703-710.
Pieters GF, van Liessum PA, Smals AG, van Gennep JA, Benraad TJ, Kloppenborg PW. Long-term treatment of acromegaly with Sandostatin (SMS 201-995): normalization of most anomalous growth hormone responses. Acta Endocrinol Suppl. 1987;286:9-18.
Timsit J, Chanson P, Larger E, et al. The effect of subcutaneous infusion versus subcutaneous injections of a somatostatin analogue (SMS 201-995) on the diurnal GH profile in acromegaly. Acta Endocrinol. 1987;116:108-112.
Beckers A, Stevenaert A, Hennen G. A new therapy for acromegaly. Rev Med Liege. 1988;43:429-432.
Cozzi R, Liuzzi A, Dallabonzana D, et al. Clinical use of the somatostatin analog SMS 201-995 in endocrinology. J Endocrinol Invest. 1988;11:737-740.
Garcia-Luna PP, Leal del Cerro A, Santos C, et al. Size changes of a growth hormone- and prolactin-producing adenoma during and after Sandostatin treatment. Horm Res. 1988;29:109-111.
Gavilan I, Santos C, Garcia-Luna PP, et al. Response of growth hormone to the acute test using GH-releasing factor 1-29 in acromegaly: comparison in the baseline situation and under treatment with prolonged-action somatostatin. Rev Clin Esp. 1988;182:187-191.
Tolis G. Long-term management of acromegaly with Sandostatin. Horm Res. 1988;29:112-114.
van Liessum PA, Pieters GF, Hermus AR, Smals AG, Kloppenborg PW. Successful treatment of ophthalmoplegia in acromegaly with the somatostatin analogue SMS 201-995. Neth J Med. 1988;32:289-292.
Chanson P, Timsit J, Masquet C, Guillausseau PJ, Warnet A, Lubetzki J. Heart failure responding to octreotide in patient with acromegaly. Lancet. 1989;1:1263-1264.
Quabbe HJ, Plockinger U. Dose-response study and long term effect of the somatostatin analog octreotide in patients with therapy-resistant acromegaly. J Clin Endocrinol Metab. 1989;68:873-881.
Sassolas G, Fossati P, Chanson P, et al. Experience of a six-month treatment with Sandostatin at increasing doses in acromegaly. Horm Res. 1989;31:51-54.
Tauber JP, Babin T, Tauber MT, et al. Long term effects of continuous subcutaneous infusion of the somatostatin analog octreotide in the treatment of acromegaly. J Clin Endocrinol Metab. 1989;68:917-924.
Harris AG, Prestele H, Herold K, Boerlin V. Long-term efficacy of Sandostatin (SMS 201-996, octreotide) in 178 acromegalic patients. In: Lamberts SWJ, ed. Sandostatin in the Treatment of Acromegaly. New York, NY: Springer-Verlag NY Inc; 1988:117-125.
Barnard LB, Grantham WG, Lamberton P, O’Dorisio TM, Jackson IMD. Treatment of resistant acromegaly with a long-acting somatostatin analog (SMS 201-995). Ann Intern Med. 1986;105:856-861.
Barkan AL, Lloyd RV, Chandler WF, et al. Preoperative treatment of acromegaly with long-acting somatostatin analog SMS 201-995: shrinkage of invasive pituitary macroadenomas and improved surgical remission rate. J Clin Endocrinol Metab. 1988;67:1040-1048.
Ho KY, Weissberger AJ, Marbach P, Lazarus L. Therapeutic efficacy of the somatostatin analog SMS 201-993 (octreotide) in acromegaly. Ann Intern Med. 1990;112:173-181.
Sassolas G, Harris AG, James-Deidier A. Long term effect of incremental doses of the somatostatin analog SMS 201-995 in 58 acromegalic patients. J Clin Endocrinol Metab. 1990;71:391-397.
Reubi JC, Landholt AM. The growth hormone responses to octreotide in acromegaly correlate with adenoma somatostatin receptor status. J Clin Endocrinol Metab. 1989;68:844-850.
Lamberts SWJ, Uitterlinden P, Verleun T. Relationship between growth hormone and somatomedin-C levels in untreated acromegaly, after surgery and radiotherapy and during medical therapy with Sandostatin (SMS 201-995). Eur J Clin Invest. 1987;17:703-710.
Barkan AL, Beitins IZ, Kelch RP. Plasma insulin-like growth factor I/somatomedin-C in acromegaly: correlation with degree of growth hormone hypersecretion. J Clin Endocrinol Metab. 1988;67:69-73.
Daughaday WH, Starkey RH, Saltman S, Gavin JR, Mills-Dunlap B, Heath-Moning E. Characterization of serum growth hormone (GH) and insulinlike growth factor I in active acromegaly with minimal elevation of serum GH. J Clin Endocrinol Metab. 1987;65:617-623.
Kvols LK, Moertell CG, O’Connell MJ, Schutt AJ, Rubin J, Hahn RG. Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N Engl J Med. 1986;315:663-666.
van Liessum PA, Hopman WPM, Pieters GFFM, et al. Postprandial gallbladder motility during long term treatment with the long-acting somatostatin analog SMS 201-995 in acromegaly. J Clin Endocrinol Metab. 1989;69:557-562.
Freedman GD, Kannel WB, Dawber TR. The epidemiology of gallbladder disease: observations in the Framingham study. J Chronic Dis. 1966;19:273-292.
